Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 treated with tocilizumab
Author
dc.contributor.author
Niño Taravilla, Carmen
Author
dc.contributor.author
Espinosa Vielma, Yazmín P.
Author
dc.contributor.author
Otaola Arca, Hugo
Author
dc.contributor.author
Poli Harlowe, Cecilia
Author
dc.contributor.author
Tapia, Lorena I.
Author
dc.contributor.author
Ortiz Fritz, Paula
Admission date
dc.date.accessioned
2021-07-15T20:47:19Z
Available date
dc.date.available
2021-07-15T20:47:19Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Pediatr. Rep. 2020, 12, 142–148
es_ES
Identifier
dc.identifier.other
10.3390/pediatric12030029
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/180628
Abstract
dc.description.abstract
We describe a case of Pediatric Inflammatory Multisystem Syndrome temporally associated
with SARS-CoV-2 (PIMS-TS) in an 8-year-old child. The patient developed multiorgan dysfunction,
including mixed shock, cardiac dysfunction with myocarditis, pneumonia, acute kidney failure,
and gastrointestinal involvement characterized by inflammation of the wall of the bowel
and pancreatitis. After treatment with Tocilizumab and corticoid therapy, he presented clinical
improvement and normalization of inflammatory markers. PIMS-TS is a new disease developed in a
small percentage of patients, so a high degree of suspicion is necessary to establish the diagnosis.
Supportive care is of paramount importance. The use of Tocilizumab to control the inflammatory
response is likely to be beneficial, but the best immunotherapeutic agent has not yet been established.
Randomized clinical studies should be run to determine the best treatment.